Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G47delta-KillerRed
- Development stage
- Preclinical
- Lead developer
- Massachusetts General Hospital
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
G47delta-KillerRed is an experimental photodynamic oncolytic virotherapy designed for the treatment of central nervous system malignancies, including high-grade gliomas and malignant meningioma. It consists of G47delta, a third-generation genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1), which has been modified to express KillerRed, a genetically encoded photosensitizing fluorescent protein. The therapeutic approach combines the direct tumor-lytic effects of the oncolytic virus with photodynamic therapy (PDT). Upon infection of tumor cells, G47delta-KillerRed expresses the KillerRed protein, which, when activated by specific light irradiation (e.g., amber LED or laser), generates reactive oxygen species (ROS) to induce further tumor cell death. This dual-mechanism strategy aims to enhance tumoricidal efficacy and is currently being investigated in preclinical models by researchers at Massachusetts General Hospital.
- Other names
- G47Δ-KillerRed
02
Targets
NECTIN1 (Poliovirus receptor-related 1)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))TMEFF2
Beyond the preview
Go deeper on G47delta-KillerRed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G47delta-KillerRed.